drugset / Trial / NCT00949234
Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
Phase 2
Completed
267 enrolled
University of California, Los Angeles
AIDS Project Los Angeles · collabLos Angeles County Department of Public Health · collabLos Angeles LGBT Center · collabThe OASIS Clinic · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this program is to evaluate an effort to provide a comprehensive package of HIV prevention services of which post-exposure prophylaxis (medicines that may help prevent HIV infection after an exposure) can be a part. It will also include risk reduction information and testing for other sexually transmitted infections.
Timeline
- Start
- 2010-03
- Primary completion
- 2010-06
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamivudine | Other / unclassified | 150 mg | Oral |
| Subject | Lopinavir | Other / unclassified | 200 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 50 mg | Oral |
| Subject | Tenofovir | Small molecule | — | Oral |
| Subject | Zidovudine | Small molecule | 300 mg | Oral |
| Subject | emtricitabine | Other / unclassified | — | Oral |